^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)

i
Other names: Cytochrome P450 Family 3 Subfamily A Member 4, Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase), Polypeptide 4, Cytochrome P450, Family 3, Subfamily A, Polypeptide 4, Albendazole Monooxygenase (Sulfoxide-Forming), 1,4-Cineole 2-Exo-Monooxygenase, 1,8-Cineole 2-Exo-Monooxygenase, Cholesterol 25-Hydroxylase, Albendazole Sulfoxidase, Quinine 3-Monooxygenase, Cytochrome P450 NF-25, Cytochrome P450-PCN1, Cytochrome P450 3A4, Cytochrome P450 3A3, Cytochrome P450 HLp, Nifedipine Oxidase, CYPIIIA3, CYPIIIA4, CYP3A3, Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase), Polypeptide 3, Taurochenodeoxycholate 6-Alpha-Hydroxylase, Glucocorticoid-Inducible P450, P450-III, Steroid Inducible, P450PCN1, P450C3, CYP3A4, CYP3A, NF-25, VDDR3, CP33, CP34, HLP
5d
Simultaneous chromatographic quantification of upadacitinib, nilotinib, and tryptophan decoding myeloid leukemia and liver cancer integrated with ELISA and Flow cytometry. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
Fluorescence-based determination using flow cytometry with ELISA revealed a pioneer significant pro-apoptotic effect of Upadacitinib in HCC cells via modulation of the Bax/Bcl-2 axis with combination therapy showing superior anticancer effect compared to standard chemotherapy of Doxorubicin (DOX). Sustainability evaluation using AGREE (greenness) and BAGI (blueness) with RGB12 algorithm (whiteness) and spider-diagram visualization, in addition to the recently launched Multi-Color Assessment (MA) tool to confirm the method's multidimensional eco-efficiency in strong alignment with the United Nations Sustainable Development Goals (SDGs). This study further harnesses the Need-Quality-Sustainability (NQS) index and Koel's pyramid principles for holistic evaluation and benchmarking against reported approaches toward sustainable analytical oncology with personalized medicine.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
doxorubicin hydrochloride • Tasigna (nilotinib)
6d
Structure-based screening and molecular dynamics of phytophytochemicals against pseudomonas aeruginosa quorum sensing systems. (PubMed, J Genet Eng Biotechnol)
This study provides in-silico mechanistic support for phytochemical-mediated QS inhibition in P. aeruginosa, with berberine emerging as a lead candidate for further development. Our integrative approach map water displacement hotspots in PqsR (GIST) and detect a baicalin-linked distal helix perturbation (DSSP) consistent with allostery, and bridges computational prediction and therapeutic design, offering new strategies to combat antimicrobial resistance through virulence attenuation.
Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
6d
Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients. (PubMed, PLoS One)
UGT1A1*6 and ABCC2 -24C > T variants emerge as potential predictors of irinotecan-induced neutropenia, while UGT1A1*6 and SLCO1B1 521T > C may serve as markers of prolonged PFS in Thai patients. Validation through larger prospective studies is essential to confirm and refine these genetic associations.
Retrospective data • Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • ABCC5 (ATP Binding Cassette Subfamily C Member 5) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • ABCG1 (ATP Binding Cassette Subfamily G Member 1)
|
irinotecan
8d
The Impact of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Cyclosporine Concentration in Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation. (PubMed, Clin Transplant)
Cyclosporine A (CsA) is used as graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT)...In conclusion, patients carrying rs776746 or rs2740574 achieved higher CsA trough levels and may require lower initial dosing. Future research should assess whether genotype-guided CsA dosing improves achieving therapeutic levels and reduces early toxicity or suboptimal immunosuppression post-HSCT.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
|
cyclosporin A microemulsion
9d
Recent advances in gut microbiota metabolite regulation of hepatic pregnane X receptor. (PubMed, Front Immunol)
Dysregulated PXR signaling underlies bile acid imbalance, mitochondrial dysfunction, and chemoresistance, driving clinical development of interventions including probiotic modulation of LCA/DCA balance, triptolide-mediated PXR activation, and structure-based PXR-targeted drug design. These findings highlight the microbiota-PXR axis as a critical determinant of drug response heterogeneity and a promising therapeutic target for metabolic liver disorders and refractory malignancies.
Review • Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
14d
Clinical • P3 data • Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • SLCO2B1 (Solute Carrier Organic Anion Transporter Family Member 2B1) • UGT1A4 (UDP Glucuronosyltransferase Family 1 Member A4)
|
Xtandi (enzalutamide) • abiraterone acetate
14d
Unraveling enantioselective metabolism: Human cytochrome P450s in arachidonic acid biotransformation. (PubMed, Drug Metab Dispos)
The findings indicate that major P450 differ in the magnitude of their hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acid formation rates, which is a significant for studying diseases that is known to be influenced by alterations in these pathways. Altered enantioselectivity could have implications in diseases such as hypertension, cancer, inflammation, and cardiovascular disorders.
Journal
|
CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1)
16d
Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes. (PubMed, Pharmacogenomics)
AA genotype at G681A in low BMI patients showed the poorest chemotherapy response and lowest PFS (HR>1). CYP2C19 variants (AA) may serve as predictive markers for non-responsiveness towards AC-T chemotherapy in low BMI BC patients, highlighting the need for genetic counselling and nutritional support to improve treatment outcomes.
Journal
|
CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
cyclophosphamide
17d
Ceritinib-ibuprofen synergistic hepatotoxicity: Insights from real-world data and liver organoid models. (PubMed, Toxicology)
Together, these findings provide a multidimensional understanding of DILI risks associated with ceritinib combination therapies. By integrating pharmacovigilance signals with physiologically relevant in vitro validation, this study highlights the utility of the human liver organoids for elucidating the mechanisms of hepatotoxicity insights and supporting safer prescribing practices, especially when ceritinib is co-administered with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen in real-world clinical settings.
Journal • Real-world evidence
|
ALK (Anaplastic lymphoma kinase) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
Zykadia (ceritinib)
22d
Integrative Machine Learning Model for Overall Survival Prediction in Breast Cancer Using Clinical and Transcriptomic Data. (PubMed, Biology (Basel))
Among ML models, XGBoost demonstrated the highest performance (accuracy 98%, sensitivity 98%, specificity 97%, F1-score 0.99, AUC 0.86), outperforming other algorithms. These findings indicate that age-related transcriptomic changes impact survival in Luminal A breast cancer and that an ML-based integrative approach combining clinical and molecular variables provides superior prognostic accuracy, supporting its potential for clinical application.
Journal
|
AKT2 (V-akt murine thymoma viral oncogene homolog 2) • FOXO3 (Forkhead box O3) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
24d
Preliminary Assessment of Cytotoxic Effects of Murraya koenigii Toluene Extracts on PA1 Cells via LC-MS, In Vitro, and In Silico Approaches. (PubMed, Biotechnol Appl Biochem)
The study underscores the utility of toluene-based extraction in expanding MK's phytochemical landscape and supports its therapeutic promise in oncology and infectious disease contexts. As this study represents a preliminary evaluation, further mechanistic validation, compound isolation, and broad-spectrum screening are essential to confirm the bioactivity and pharmacological relevance of these leads.
Preclinical • Journal
|
CDK4 (Cyclin-dependent kinase 4) • TNFA (Tumor Necrosis Factor-Alpha) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
27d
Characterization of In Vitro metabolic profiles of crepidatin in human liver microsomes and hepatocytes using HPLC-MS/MS and HPLC-Q-Orbitrap-HRMS. (PubMed, J Pharm Biomed Anal)
Crepidatin was primarily metabolized by CYP3A4, 2C8, 2C19, UGT1A1, UGT1A8, and UGT1A9. This study describes the first integrated HPLC-MS/MS and HPLC-Q-Orbitrap-HRMS method for its in vitro metabolic profiling, and the results facilitate prediction of in vivo pharmacokinetics.
Preclinical • Journal
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • UGT1A8 (UDP Glucuronosyltransferase Family 1 Member A8)